{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T01:27:47Z","timestamp":1755221267866,"version":"3.43.0"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:p>Consensus guidelines for genotype-guided fluoropyrimidine dosing based on variation in the dihydropyrimidine dehydrogenase (DPYD) gene before treatment have been firmly established. The prior pharmacogenetic report avoids the serious toxicity that inevitably occurred in a non-negligible percentage of the treated patients. The precise description of the allelic distribution of the variants of interest in our reference populations is information of great interest for the management of the prescription of these antineoplastic drugs. We characterized the allelic distribution of the UGT1A1*28 variant (rs3064744), as well as the DPYD*2A (rs3918290) variant, c.1679T&gt;G (rs55886062), c.2846A&gt;T (rs67376798) and c.1129-5923C&gt;G (rs75017182; HapB3) in series of 5251 patients who are going to receive treatment with irinotecan and fluoropyrimidines, representative of Valencian, Aragonese and Western Andalusian populations.<\/jats:p>","DOI":"10.1097\/fpc.0000000000000530","type":"journal-article","created":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T10:00:52Z","timestamp":1710496852000},"page":"166-169","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Diversity of oncopharmacogenetic profile within Spanish population"],"prefix":"10.1097","volume":"34","author":[{"given":"Irene","family":"Ferrer Bolufer","sequence":"first","affiliation":[{"name":"Genetics Laboratory, Clinical Analysis Service, General Hospital Consortium of Valencia, Valencia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ximo","family":"Galiana Vall\u00e9s","sequence":"additional","affiliation":[{"name":"Genetics Laboratory, Clinical Analysis Service, General Hospital Consortium of Valencia, Valencia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Izquierdo \u00c1lvarez","sequence":"additional","affiliation":[{"name":"Genetics Laboratory, Clinical Biochemistry Service, Miguel Servet University Hospital, Zaragoza"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Serrano Mira","sequence":"additional","affiliation":[{"name":"Human Genetics Unit, Clinical Analysis Service, Juan Ram\u00f3n Jim\u00e9nez Hospital, Huelva"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carola","family":"Guzm\u00e1n Luj\u00e1n","sequence":"additional","affiliation":[{"name":"Genetics Laboratory, Clinical Analysis Service, General Hospital Consortium of Valencia, Valencia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Safont Aguilera","sequence":"additional","affiliation":[{"name":"Oncology Service, General Hospital Consortium of Valencia, Valencia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Gonz\u00e1lez Taranc\u00f3n","sequence":"additional","affiliation":[{"name":"Genetics Laboratory, Clinical Biochemistry Service, Miguel Servet University Hospital, Zaragoza"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matilde","family":"Bola\u00f1os Naranjo","sequence":"additional","affiliation":[{"name":"Medical Oncology Service, Juan Ram\u00f3n Jim\u00e9nez Hospital, Huelva"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Carrasco Salas","sequence":"additional","affiliation":[{"name":"Human Genetics Unit, Clinical Analysis Service, Juan Ram\u00f3n Jim\u00e9nez Hospital, Huelva"},{"name":"Genetics Commission, Spanish Society of Laboratory Medicine, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Santamar\u00eda Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Genetics Laboratory, Clinical Biochemistry Service, Miguel Servet University Hospital, Zaragoza"},{"name":"Genetics Commission, Spanish Society of Laboratory Medicine, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"Rodr\u00edguez-L\u00f3pez","sequence":"additional","affiliation":[{"name":"Genetics Laboratory, Clinical Analysis Service, General Hospital Consortium of Valencia, Valencia"},{"name":"Genetics Commission, Spanish Society of Laboratory Medicine, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,3,18]]},"reference":[{"key":"R1-20250808","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJM200009283431302","article-title":"Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.","volume":"343","author":"Saltz","year":"2000","journal-title":"N Engl J Med"},{"key":"R2-20250808","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s13402-020-00529-1","article-title":"Pharmacogenomics of 5-fluorouracil in colorectal cancer: review and update.","volume":"43","author":"Xie","year":"2020","journal-title":"Cell Oncol (Dordrecht)"},{"key":"R4-20250808","doi-asserted-by":"crossref","first-page":"e13699","DOI":"10.1111\/cts.13699","article-title":"Updated DPYD HapB3 haplotype structure and implications for pharmacogenomic testing.","volume":"17","author":"Turner","year":"2024","journal-title":"Clin Transl Sci"},{"key":"R5-20250808","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1093\/annonc\/mdf337","article-title":"Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity.","volume":"13","author":"Xu","year":"2002","journal-title":"Ann Oncol"},{"key":"R6-20250808","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1056\/NEJM199511023331802","article-title":"The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert\u2019s syndrome.","volume":"333","author":"Bosma","year":"1995","journal-title":"N Engl J Med"},{"key":"R7-20250808","doi-asserted-by":"crossref","first-page":"1","DOI":"10.26502\/jatr.33","article-title":"Phenotypic variability in expressivity and deleterious capability of the homozygous UGT1A1*28 genotype.","volume":"5","author":"Rodr\u00edguez-L\u00f3pez","year":"2023","journal-title":"J Anal Tech Res"},{"key":"R8-20250808","doi-asserted-by":"crossref","first-page":"e304","DOI":"10.1093\/oncolo\/oyad077","article-title":"Allelic Frequency of DPYD genetic variants in patients with cancer in Spain: the photoDPYD study.","volume":"28","author":"Miarons","year":"2023","journal-title":"Oncologist"},{"key":"R9-20250808","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.ajhg.2019.04.017","article-title":"Estimating the effectiveness of DPYD genotyping in Italian individuals suffering from cancer based on the cost of chemotherapy-induced toxicity.","volume":"104","author":"Fragoulakis","year":"2019","journal-title":"Am J Hum Genet"},{"key":"R10-20250808","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/s41431-019-0540-0","article-title":"Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines.","volume":"28","author":"Lunenburg","year":"2020","journal-title":"Eur J Hum Genet"},{"key":"R11-20250808","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/cpt.911","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update.","volume":"103","author":"Amstutz","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"R12-20250808","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/humu.1380040302","article-title":"The Cystic Fibrosis Genetic Analysis Consortium (CFGAC). Population variation of common CF mutations.","volume":"4","author":"Kazazian","year":"1994","journal-title":"Hum Mutat"},{"key":"R13-20250808","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.3390\/pharmaceutics15041286","article-title":"A comprehensive analysis of 21 actionable pharmacogenes in the Spanish population: from genetic characterisation to clinical impact.","volume":"15","author":"N\u00fa\u00f1ez-Torres","year":"2023","journal-title":"Pharmaceutics"},{"key":"R14-20250808","doi-asserted-by":"crossref","first-page":"663","DOI":"10.3390\/curroncol30010051","article-title":"DPYD exon 4 deletion associated with fluoropyrimidine toxicity and importance of copy number variation.","volume":"30","author":"Wigle","year":"2023","journal-title":"Curr Oncol"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0000000000000530","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T14:00:43Z","timestamp":1754661643000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0000000000000530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,18]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0000000000000530","relation":{},"ISSN":["1744-6872"],"issn-type":[{"type":"print","value":"1744-6872"}],"subject":[],"published":{"date-parts":[[2024,3,18]]}}}